Financhill
Buy
54

SCPH Quote, Financials, Valuation and Earnings

Last price:
$3.32
Seasonality move :
-3.25%
Day range:
$3.32 - $3.57
52-week range:
$1.94 - $5.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.02x
P/B ratio:
10.87x
Volume:
272K
Avg. volume:
377.5K
1-year change:
-0.99%
Market cap:
$185M
Revenue:
$36.3M
EPS (TTM):
-$1.91

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SCPH
scPharmaceuticals
$11.6M -$0.29 91.38% -32.27% $15.17
BTAI
BioXcel Therapeutics
$350K -$3.04 -39.86% -78.16% $48.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
RGNX
Regenxbio
$105.4M $0.49 83.3% -0.45% $32.00
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SCPH
scPharmaceuticals
$3.51 $15.17 $185M -- $0.00 0% 4.02x
BTAI
BioXcel Therapeutics
$1.37 $48.00 $8.3M -- $0.00 0% 2.41x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.16x
OGEN
Oragenics
$0.19 $1.00 $4.1M -- $0.00 0% 1.84x
RGNX
Regenxbio
$9.86 $32.00 $494.6M -- $0.00 0% 3.20x
TOVX
Theriva Biologics
$0.46 $7.00 $3.8M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SCPH
scPharmaceuticals
111.16% 0.532 38.6% 4.38x
BTAI
BioXcel Therapeutics
687.29% -2.205 950.68% 1.21x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
OGEN
Oragenics
-- 3.254 -- --
RGNX
Regenxbio
-- 0.116 -- 2.69x
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SCPH
scPharmaceuticals
$8.3M -$17.8M -148.54% -624.21% -156.2% -$17.1M
BTAI
BioXcel Therapeutics
$154K -$10.1M -197.27% -- -1941.07% -$12M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
RGNX
Regenxbio
$85.6M $12.1M -50.09% -50.09% 16.46% $32.6M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

scPharmaceuticals vs. Competitors

  • Which has Higher Returns SCPH or BTAI?

    BioXcel Therapeutics has a net margin of -167.99% compared to scPharmaceuticals's net margin of -4317.86%. scPharmaceuticals's return on equity of -624.21% beat BioXcel Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SCPH
    scPharmaceuticals
    70.47% -$0.37 $45.9M
    BTAI
    BioXcel Therapeutics
    91.67% -$1.50 $15.4M
  • What do Analysts Say About SCPH or BTAI?

    scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 332.72%. On the other hand BioXcel Therapeutics has an analysts' consensus of $48.00 which suggests that it could grow by 3403.65%. Given that BioXcel Therapeutics has higher upside potential than scPharmaceuticals, analysts believe BioXcel Therapeutics is more attractive than scPharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SCPH
    scPharmaceuticals
    4 0 0
    BTAI
    BioXcel Therapeutics
    1 0 0
  • Is SCPH or BTAI More Risky?

    scPharmaceuticals has a beta of 0.170, which suggesting that the stock is 83.044% less volatile than S&P 500. In comparison BioXcel Therapeutics has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.161%.

  • Which is a Better Dividend Stock SCPH or BTAI?

    scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioXcel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. BioXcel Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SCPH or BTAI?

    scPharmaceuticals quarterly revenues are $11.8M, which are larger than BioXcel Therapeutics quarterly revenues of $168K. scPharmaceuticals's net income of -$19.7M is lower than BioXcel Therapeutics's net income of -$7.3M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while BioXcel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 4.02x versus 2.41x for BioXcel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SCPH
    scPharmaceuticals
    4.02x -- $11.8M -$19.7M
    BTAI
    BioXcel Therapeutics
    2.41x -- $168K -$7.3M
  • Which has Higher Returns SCPH or NBY?

    NovaBay Pharmaceuticals has a net margin of -167.99% compared to scPharmaceuticals's net margin of -49.65%. scPharmaceuticals's return on equity of -624.21% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    SCPH
    scPharmaceuticals
    70.47% -$0.37 $45.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About SCPH or NBY?

    scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 332.72%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.91%. Given that scPharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe scPharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SCPH
    scPharmaceuticals
    4 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is SCPH or NBY More Risky?

    scPharmaceuticals has a beta of 0.170, which suggesting that the stock is 83.044% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock SCPH or NBY?

    scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SCPH or NBY?

    scPharmaceuticals quarterly revenues are $11.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. scPharmaceuticals's net income of -$19.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 4.02x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SCPH
    scPharmaceuticals
    4.02x -- $11.8M -$19.7M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns SCPH or OGEN?

    Oragenics has a net margin of -167.99% compared to scPharmaceuticals's net margin of --. scPharmaceuticals's return on equity of -624.21% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SCPH
    scPharmaceuticals
    70.47% -$0.37 $45.9M
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About SCPH or OGEN?

    scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 332.72%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than scPharmaceuticals, analysts believe Oragenics is more attractive than scPharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SCPH
    scPharmaceuticals
    4 0 0
    OGEN
    Oragenics
    0 1 0
  • Is SCPH or OGEN More Risky?

    scPharmaceuticals has a beta of 0.170, which suggesting that the stock is 83.044% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock SCPH or OGEN?

    scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SCPH or OGEN?

    scPharmaceuticals quarterly revenues are $11.8M, which are larger than Oragenics quarterly revenues of --. scPharmaceuticals's net income of -$19.7M is lower than Oragenics's net income of -$2.2M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 4.02x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SCPH
    scPharmaceuticals
    4.02x -- $11.8M -$19.7M
    OGEN
    Oragenics
    1.84x -- -- -$2.2M
  • Which has Higher Returns SCPH or RGNX?

    Regenxbio has a net margin of -167.99% compared to scPharmaceuticals's net margin of 6.83%. scPharmaceuticals's return on equity of -624.21% beat Regenxbio's return on equity of -50.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    SCPH
    scPharmaceuticals
    70.47% -$0.37 $45.9M
    RGNX
    Regenxbio
    96.14% $0.12 $274.2M
  • What do Analysts Say About SCPH or RGNX?

    scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 332.72%. On the other hand Regenxbio has an analysts' consensus of $32.00 which suggests that it could grow by 224.54%. Given that scPharmaceuticals has higher upside potential than Regenxbio, analysts believe scPharmaceuticals is more attractive than Regenxbio.

    Company Buy Ratings Hold Ratings Sell Ratings
    SCPH
    scPharmaceuticals
    4 0 0
    RGNX
    Regenxbio
    6 1 0
  • Is SCPH or RGNX More Risky?

    scPharmaceuticals has a beta of 0.170, which suggesting that the stock is 83.044% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.115, suggesting its more volatile than the S&P 500 by 11.488%.

  • Which is a Better Dividend Stock SCPH or RGNX?

    scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SCPH or RGNX?

    scPharmaceuticals quarterly revenues are $11.8M, which are smaller than Regenxbio quarterly revenues of $89M. scPharmaceuticals's net income of -$19.7M is lower than Regenxbio's net income of $6.1M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 4.02x versus 3.20x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SCPH
    scPharmaceuticals
    4.02x -- $11.8M -$19.7M
    RGNX
    Regenxbio
    3.20x -- $89M $6.1M
  • Which has Higher Returns SCPH or TOVX?

    Theriva Biologics has a net margin of -167.99% compared to scPharmaceuticals's net margin of --. scPharmaceuticals's return on equity of -624.21% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SCPH
    scPharmaceuticals
    70.47% -$0.37 $45.9M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About SCPH or TOVX?

    scPharmaceuticals has a consensus price target of $15.17, signalling upside risk potential of 332.72%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1409.6%. Given that Theriva Biologics has higher upside potential than scPharmaceuticals, analysts believe Theriva Biologics is more attractive than scPharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SCPH
    scPharmaceuticals
    4 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is SCPH or TOVX More Risky?

    scPharmaceuticals has a beta of 0.170, which suggesting that the stock is 83.044% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock SCPH or TOVX?

    scPharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. scPharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SCPH or TOVX?

    scPharmaceuticals quarterly revenues are $11.8M, which are larger than Theriva Biologics quarterly revenues of --. scPharmaceuticals's net income of -$19.7M is lower than Theriva Biologics's net income of -$4.3M. Notably, scPharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for scPharmaceuticals is 4.02x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SCPH
    scPharmaceuticals
    4.02x -- $11.8M -$19.7M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will DigitalOcean Stock Bounce Back?
Will DigitalOcean Stock Bounce Back?

DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
66
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
54
AAP alert for May 23

Advance Auto Parts [AAP] is down 0.98% over the past day.

Buy
67
IONQ alert for May 23

IonQ [IONQ] is down 0.48% over the past day.

Buy
75
URBN alert for May 23

Urban Outfitters [URBN] is down 1.24% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock